Skip to main content
Premium Trial:

Request an Annual Quote

Compugen to Collaborate with Teva on Toxicity Biomarker Discovery

NEW YORK (GenomeWeb News) - Compugen today said it has signed a collaboration with Teva Pharmaceuticals to discovery biomarkers that could predict nephrotoxicity.
 
The agreement also may be expanded to include biomarker development for hepatoxicity and cardiotoxicity, Compugen said.
 
Under the agreement, Compugen will use its computational tools and nucleic acid testing technologies to analyze biological samples collected by Teva in a preclinical study.
 
Teva will have a license to use the discovered markers for its internal R&D programs, while Compugen has retained rights to license the markers to other companies, as well as rights for internal use.
 
Ana Cohen-Dayag, Compugen’s vice president of diagnostic biomarkers, said in a statement that the company will use predictive platforms it developed for immunoassay diagnostic collaborations to develop the biomarkers, which will enable early-stage identification of toxicity. 

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.